15基因表达谱与PRAME联合作为葡萄膜黑色素瘤整合预后检测:眼肿瘤协作组研究第2号(COOG2.1)首次报告
COOG2前瞻性纳入26个北美中心1577例脉络膜和/或睫状体葡萄膜黑色素瘤患者,验证15基因表达谱(15-GEP)联合PRAME RNA表达的整合预后分类器。5年无转移生存率从1类/PRAME阴性95.6%至2类/PRAME阳性44.8%递减,多变量分析示15-GEP为最重要独立预测因子(HR 5.95),PRAME次之(HR 1.82),肿瘤直径为唯一提供额外预后信息的临床变量。
要点
- 15-GEP为独立预后最重要因子(HR 5.95,95%CI 4.43-7.99,P<.001),PRAME次之(HR 1.82,95%CI 1.42-2.33,P<.001)。
- 5年MFS:1类/PRAME(-) 95.6%(95%CI 93.9-97.4),1类/PRAME(+) 80.6%(95%CI 73.9-87.9),2类/PRAME(-) 58.3%(95%CI 51.1-66.4),2类/PRAME(+) 44.8%(95%CI 37.9-52.8)。
- 肿瘤直径是唯一提供额外预后信息的临床变量。
核心结论
- 在迄今规模最大的葡萄膜黑色素瘤前瞻性多中心预后生物标志物研究中,整合15-GEP/PRAME分类器较15-GEP单独及临床预后变量具有更优的预后准确性。
- 肿瘤直径是唯一提供额外预后信息的临床变量。
- 该预后分类器为葡萄膜黑色素瘤患者的风险调整转移监测和辅助试验分层提供了先进工具。
研究设计与样本
- 前瞻性多中心预后生物标志物研究(COOG2),纳入脉络膜和/或睫状体葡萄膜黑色素瘤患者1577例,来自26个北美中心,前瞻性监测,所有患者均有15-GEP(1类或2类)和PRAME表达状态(阴性或阳性)检测结果,主要终点为无转移生存期(MFS)。
主要发现
- 15-GEP 1类1082例(68.6%),2类495例(31.4%);PRAME阴性1106例(70.1%),阳性471例(29.9%)。
- 5年MFS:1类/PRAME(-) 95.6%(95%CI 93.9-97.4),1类/PRAME(+) 80.6%(95%CI 73.9-87.9),2类/PRAME(-) 58.3%(95%CI 51.1-66.4),2类/PRAME(+) 44.8%(95%CI 37.9-52.8)。
- 多变量Cox比例风险分析中,15-GEP是MFS最重要的独立预测因子(HR 5.95,95%CI 4.43-7.99,P<.001),PRAME状态次之(HR 1.82,95%CI 1.42-2.33,P<.001)。
- 唯一显示额外预后价值的临床变量是肿瘤直径。
关键数值与推荐
- 15-GEP为MFS最重要的独立预测因子(HR 5.95,95%CI 4.43-7.99,P<.001)。
- PRAME状态为MFS独立预测因子(HR 1.82,95%CI 1.42-2.33,P<.001)。
- 5年MFS:1类/PRAME(-) 95.6%(95%CI 93.9-97.4),1类/PRAME(+) 80.6%(95%CI 73.9-87.9),2类/PRAME(-) 58.3%(95%CI 51.1-66.4),2类/PRAME(+) 44.8%(95%CI 37.9-52.8)。
- 肿瘤直径是唯一提供额外预后信息的临床变量。
临床怎么用
- 该整合15-GEP/PRAME预后分类器可为葡萄膜黑色素瘤患者风险调整的转移监测和辅助试验分层提供依据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSEValidated and accurate prognostic testing is critical for precision medicine in uveal melanoma (UM). Our aims were to (1) prospectively validate an integrated prognostic classifier combining a 15-gene expression profile (15-GEP) and PRAME RNA expression and (2) identify clinical variables that enhance the prognostic accuracy of the 15-GEP/PRAME classifier.MATERIALS AND METHODSThis study included 1,577 patients with UM of the choroid and/or ciliary body who were enrolled in the Collaborative Ocular Oncology Group Study Number 2 (COOG2) and prospectively monitored across 26 North American centers. Test results for 15-GEP (class 1 or class 2) and PRAME expression status (negative or positive) were available for all patients. The primary end point was metastasis-free survival (MFS).RESULTS15-GEP was class 1 in 1,082 (68.6%) and class 2 in 495 (31.4%) patients. PRAME status was negative in 1,106 (70.1%) and positive in 471 (29.9%) patients. Five-year MFS was 95.6% (95% CI, 93.9 to 97.4) for class 1/PRAME(-), 80.6% (95% CI, 73.9 to 87.9) for class 1/PRAME(+), 58.3% (95% CI, 51.1 to 66.4) for class 2/PRAME(-), and 44.8% (95% CI, 37.9 to 52.8) for class 2/PRAME(+). By multivariable Cox proportional hazards analysis, 15-GEP was the most important independent predictor of MFS (hazard ratio [HR], 5.95 [95% CI, 4.43 to 7.99]; P < .001), followed by PRAME status (HR, 1.82 [95% CI, 1.42 to 2.33]; P < .001). The only clinical variable demonstrating additional prognostic value was tumor diameter.CONCLUSIONIn the largest prospective multicenter prognostic biomarker study performed to date in UM to our knowledge, the COOG2 study validated the superior prognostic accuracy of the integrated 15-GEP/PRAME classifier over 15-GEP alone and clinical prognostic variables. Tumor diameter was found to be the only clinical variable to provide additional prognostic information. This prognostic classifier provides an advanced resource for risk-adjusted metastatic surveillance and adjuvant trial stratification in patients with UM.
引用
- Harbour JW, Correa ZM, Schefler AC, et al. 15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1). J Clin Oncol. 2024. PMID: 39052972. doi:10.1200/JCO.24.00447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。